From the first BLA acceptance for a gene-agnostic optogenetic therapy to the first pivotal gene therapy trial in geographic atrophy, these are the retinal gene therapy milestones of 2026.
News|Articles|September 3, 2026
SPECTRUM: Early Clinical Data and Practice Experience From Global Real-World Study of Intravitreal Aflibercept (EYLEA®, Bayer AG) 8mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Advertisement
SPECTRUM: Early Clinical Data and Practice Experience From Global Real-World Study of Intravitreal Aflibercept (EYLEA®, Bayer AG) 8mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Presentation highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting
Advertisement
Related to this article
Isa S. K. Mohammed, MD, on training refractive surgeons and why lasers make global access harder than for cataract surgery.
Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.
Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.
Cataract surgery is not neutral for the vitreous.
Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.
MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models, but the authors are open about where joint learning gave ground.
Few people starting tamoxifen require an ophthalmic evaluation during the following year.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Ophthalmic care uncommon after tamoxifen initiation
2
Training refractive surgeons and expanding access to eye surgery
3
Retinal gene therapy in 2026: 13 milestones from January through October
4
Looking beyond visual acuity in macular telangiectasia
5